Outcomes
PD
DISEASE
The primary end point was survival at 6 months from the date of randomization. Secondary end points were overall survival from randomization, progression-free survival (PFS) and progression at 6 and 12 months. PFS was measured as the time from randomization to the date of investigator-assessed progressive disease (PD) according to the Response Assessment in Neuro-Oncology criteria,